AudioAbstracts

Journal of Cystic Fibrosis: Efficacy and Safety of Levofloxacin Inhalation Solution (APT-1026) in Stable Cystic Fibrosis Patients

July 31, 20163 min
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients Flume PA1, VanDevanter DR2, Morgan EE3, Dudley MN3, Loutit JS3, Bell SC4, Kerem E5, Fischer R6, Smyth AR7, Aaron SD8, Conrad D9, Geller DE10,Elborn JS11. J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4. Interpretation: In this study published in the Journal of Cystic Fibrosis in February 2016, Patrick Flume et al discuss a Phase III trial assessing the effectiveness of levofloxacin inhaled solution in cystic fibrosis patients. Cystic fibrosis lung disease is characterized by chronic respiratory tract infection with multiple bacterial species frequently dominated by Pseudomonas aeruginosa, which has been associated with accelerated lung disease progression, increased morbidity, and decreased survival. For patients with cystic fibrosis, the us

Chat About Journal of Cystic Fibrosis: Efficacy and Safety of Levofloxacin Inhalation Solution (APT-1026) in Stable Cystic Fibrosis Patients